Top

BMC Neurology

Published in:

Open Access 01-12-2022 | Meningioma | Case report

A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy

Authors: Jia-Li Zhao, Jing Liu, Ming Fang, Chen Luo, Zhen-Bang Gu, Long Huang

Published in: BMC Neurology | Issue 1/2022

Abstract

Background

Meningioma is the most common type of primary intracranial tumor with 0.1–1% of all primary meningiomas have been reported to develop into metastases. However, there is no proven therapeutic strategy for multiple metastases of meningiomas.

Case presentation

A 60-year-old female accepted total tumor resection of a right frontal lobe meningioma in September 2018, In October 2021, the patient was admitted to hospital because of cough and shortness of breath and diagnosed with metastatic meningiomas. The computed tomography (CT) scan revealed the presence of large masses in the right thoracic and abdominal cavity. After two cycles of anti-PD-1 and anti-VEGF treatment, the symptoms were relieved and the tumor was necrotic. Follow up to June 21, 2022, the patient has been given eleven cycles of the treatment every 3 weeks without tumor progression.

Conclusions

This case showed combined anti-PD-1 and anti-VEGF treatment stimulates peripheral blood immune cells to kill metastatic meningioma cells. Whether combined immunotherapy is more effective for metastatic meningioma needs further exploration.

Vakil H, Tran L, Lewis GD, Cykowski MD, Butler EB, Teh BS. Biopsy proven metastatic meningioma: A case report and review of the literature. Rep Pract Oncol Radiother. 2019;24(6):528–32. https://doi.org/10.1016/j.rpor.2019.08.002.CrossRefPubMedPubMedCentral

Wang M, Zhan R, Zhang C, Zhou Y. Multiple pulmonary metastases in recurrent intracranial meningioma: Case report and literature review. J Int Med Res. 2016;44(3):742–52. https://doi.org/10.1177/0300060515618053.CrossRefPubMedPubMedCentral

He L, Yu S, Wang L. Rapid recurrence and malignant transformation of a benign meningioma after pregnancy: a case report. Br J Neurosurg. 2020:1–3. https://doi.org/10.1080/02688697.2020.1817323.

Lamszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 2000;46:938–48. https://doi.org/10.1097/00006123-200004000-00033.CrossRefPubMed

Bernatz S, Monden D, Gessler F, Radic T, Hattingen E, Senft C, et al. Influence of VEGF-A, VEGFR-1-3, and neuropilin 1–2 on progression-free: and overall survival in WHO grade II and III meningioma patients. J Mol Histol. 2021;52(2):233–43. https://doi.org/10.1007/s10735-020-09940-2.CrossRefPubMedPubMedCentral

Grimm SA, Kumthekar P, Chamberlain MC, et al. Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. J Clin Oncol. 2015;33:2055–2055.CrossRef

Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams JT, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol. 2016;129(2):281–8. https://doi.org/10.1007/s11060-016-2172-3.CrossRefPubMed

Guo X, Wang S, Wang Y, Ma W. Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated IDH wild-type glioblastoma. Neuro Oncol. 2021;23(4):699–701. https://doi.org/10.1093/neuonc/noab005.CrossRefPubMedPubMedCentral

Bi WL, Nayak L, Meredith DM, et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022;24(1):101–13. https://doi.org/10.1093/neuonc/noab118.CrossRefPubMed

10.

Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022;13(1):1325. https://doi.org/10.1038/s41467-022-29052-7.CrossRefPubMedPubMedCentral

11.

Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475–85. https://doi.org/10.1038/s12276-020-00500-y.CrossRefPubMedPubMedCentral

Title: A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
Authors: Jia-Li Zhao
Jing Liu
Ming Fang
Chen Luo
Zhen-Bang Gu
Long Huang
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Meningioma
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Computed Tomography
Metastasis
Computed Tomography
Meningioma
Published in: BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-022-02919-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy

Abstract

Background

Case presentation

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

A prospective study on the application of HINTS in distinguishing the localization of acute vestibular syndrome

Study protocol of transcranial electrical stimulation at alpha frequency applied during rehabilitation: A randomized controlled trial in chronic stroke patients with visuospatial neglect

Risk factors for aneurysm rupture among Kazakhs: findings from a national tertiary

Predictors of recurrence of chronic subdural haematoma in a cohort study of patients presenting in a sub-Saharan African teaching hospital

Prolonged neurologic deficits with brain MRI changes following ECT in an adolescent with a CACNA1a-related disorder; a case report

Unusual neurologic manifestations of Vogt-Koyanagi-Harada disease: a systematic literature review